antibody

Urokinase Plasminogen Activator (uPA) discontinued

U1820-11B

100 ul

monoclonal

mouse

nonconjugated

9B12

Urokinase Plasminogen Activator (uPA) discontinued

mouse

Mab

Antibodies

100 ul

9B12

IgG1

Urokinase plasminogen activator (uPA) is a serine protease. It converts the abundant proenzyme plasminogen to active plasmin and plays a key role in cancer invasion and a variety of tissue remodelling processes such as wound healing, mammary gland involution and placental development. Elevated levels of uPA are associated with poor prognosis in many types of cancer. Applications: Suitable for use in ELISA, Western Blot, Flow Cytometry, Immunofluorescence and Immunohistochemistry. Other applications have not been tested. Recommended Dilutions: Immunohistochemistry: Frozen sections Western Blot: Reacts with non-reduced uPA but not with reduced uPA. Optimal dilutions to be determined by the researcher. Storage and Stability: May be stored at 4°C for short-term only. Aliquot to avoid repeated freezing and thawing. Store at -20°C. Aliquots are stable for 12 months after receipt. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.

Hu

Native human uPA

Recognizes the beta chain of human uPA. Does not react with human tissue plasminogen activator (tPA) or with other human plasma proteins. Binds single and two-chain uPA and uPA/PAI-1 complexes. A reaction is seen with LMW-uPA but not with amino terminal fregment (ATF).

Purified by Protein A affinity chromatography.

Supplied as a liquid in PBS, pH 7.4, and 15mM sodium azide.

~1mg/ml

Product Type: Mab Isotype: IgG1 Clone No: 9B12 Host: mouse Source: human Concentration: ~1mg/ml Form: Supplied as a liquid in PBS, pH7.4, and 15mM sodium azide. Purity: Purified by Protein A affinity chromatography. Immunogen: Native human uPA Specificity: Recognizes the beta chain of human uPA. Does not react with human tissue plasminogen activator (tPA) or with other human plasma proteins. Binds single and two-chain uPA and uPA/PAI-1 complexes. A reaction is seen with LMW-uPA but not with amino terminal fregment (ATF). Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications without the expressed written authorization of United States Biological.

E FC IF IHC WB

-20°C

1. Danø K, Andreasen PA, Grøndahl-Hansen J, Kristensen P, Nielsen LS, Skriver L (1985) Plasminogen activators, tissue degradation, and cancer. Adv Cancer Res 44:139-266. 2. Andreasen PA, Kjøller L, Christensen L, Duffey MJ (1997) The urokinase plasminogen activator system in cancer metastasis. Int J Cancer 2:1-22. 3. Danø K, Behrendt N, Høyer-Hansen G, Johnsen M, Lund LR, Ploug M, Rømer J (2005) Plasminogen activation and cancer. Thromb Haem 93:676-681. 4. Harbeck N, Kates RE, Look MP (2002) Enhanced benefit from adjuvant chemotherapy in breast cancer patients classified high-risk acording to urokinase -type plasminogen activator and plasminogen activator inhibitor type 1 (n=3424). Cancer Res 62:4617-22. 5. Pedersen AN, Høyer-Hansen G, Brünner N, Clark GM, Larsen B, Poulsen HS, Danø K, Stephens RW (1997) The complex between urokinase plasminogen activator and its type-1 inhibitor in breast cancer extracts quantitated by ELISA. J Imm Meth 203:55-65. 6. Kaltoft K, Nielsen LS, Zeuthen J, Danø K (1982) Monoclonal antibody that specifically inhibits a human Mr 52,000 plasminogen-activating enzyme. Proc Natl Acad Sci USA 79:3720-3723. 7. Plesner T, Ploug M, Ellis V, Rønne E, Høyer-Hansen G, Wittrup M, Pedersen TL, Tscherning T, Danø K, Hansen NE ( 1994) The receptor for urokinase-type plasminogen activator and urokinase is translocated from two distinctintracellular compartments to the pl asma membrane on stimulation of human neutrophils. Blood 83:808-815.